tetano
Editor, Senior Moderator
Nat Commun
. 2025 May 10;16(1):4351.
doi: 10.1038/s41467-025-59677-3. Structural basis of TMPRSS11D specificity and autocleavage activation
Bryan J Fraser[SUP] 1 2 [/SUP], Ryan P Wilson[SUP] 3 [/SUP], Sára Ferková[SUP] 4 5 [/SUP], Olzhas Ilyassov[SUP] 3 [/SUP], Jackie Lac[SUP] 3 [/SUP], Aiping Dong[SUP] 3 [/SUP], Yen-Yen Li[SUP] 3 [/SUP], Alma Seitova[SUP] 3 [/SUP], Yanjun Li[SUP] 3 [/SUP], Zahra Hejazi[SUP] 3 [/SUP], Tristan M G Kenney[SUP] 6 7 [/SUP], Linda Z Penn[SUP] 6 7 [/SUP], Aled Edwards[SUP] 3 6 [/SUP], Richard Leduc[SUP] 4 5 [/SUP], Pierre-Luc Boudreault[SUP] 4 5 [/SUP], Gregg B Morin[SUP] 8 9 10 [/SUP], François Bénard[SUP] 11 12 [/SUP], Cheryl H Arrowsmith[SUP] 13 14 15 [/SUP]
Affiliations
Transmembrane Protease, Serine-2 (TMPRSS2) and TMPRSS11D are human proteases that enable SARS-CoV-2 and Influenza A/B virus infections, but their biochemical mechanisms for facilitating viral cell entry remain unclear. We show these proteases spontaneously and efficiently cleave their own zymogen activation motifs, activating their broader protease activity on cellular substrates. We determine TMPRSS11D co-crystal structures with a native and an engineered activation motif, revealing insights into its autocleavage activation and distinct substrate binding cleft features. Leveraging this structural data, we develop nanomolar potency peptidomimetic inhibitors of TMPRSS11D and TMPRSS2. We show that a broad serine protease inhibitor that underwent clinical trials for TMPRSS2-targeted COVID-19 therapy, nafamostat mesylate, was rapidly cleaved by TMPRSS11D and converted to low activity derivatives. In this work, we develop mechanistic insights into human protease viral tropism and highlight both the strengths and limitations of existing human serine protease inhibitors, informing future drug discovery efforts targeting these proteases.
. 2025 May 10;16(1):4351.
doi: 10.1038/s41467-025-59677-3. Structural basis of TMPRSS11D specificity and autocleavage activation
Bryan J Fraser[SUP] 1 2 [/SUP], Ryan P Wilson[SUP] 3 [/SUP], Sára Ferková[SUP] 4 5 [/SUP], Olzhas Ilyassov[SUP] 3 [/SUP], Jackie Lac[SUP] 3 [/SUP], Aiping Dong[SUP] 3 [/SUP], Yen-Yen Li[SUP] 3 [/SUP], Alma Seitova[SUP] 3 [/SUP], Yanjun Li[SUP] 3 [/SUP], Zahra Hejazi[SUP] 3 [/SUP], Tristan M G Kenney[SUP] 6 7 [/SUP], Linda Z Penn[SUP] 6 7 [/SUP], Aled Edwards[SUP] 3 6 [/SUP], Richard Leduc[SUP] 4 5 [/SUP], Pierre-Luc Boudreault[SUP] 4 5 [/SUP], Gregg B Morin[SUP] 8 9 10 [/SUP], François Bénard[SUP] 11 12 [/SUP], Cheryl H Arrowsmith[SUP] 13 14 15 [/SUP]
Affiliations
- PMID: 40348740
- DOI: 10.1038/s41467-025-59677-3
Transmembrane Protease, Serine-2 (TMPRSS2) and TMPRSS11D are human proteases that enable SARS-CoV-2 and Influenza A/B virus infections, but their biochemical mechanisms for facilitating viral cell entry remain unclear. We show these proteases spontaneously and efficiently cleave their own zymogen activation motifs, activating their broader protease activity on cellular substrates. We determine TMPRSS11D co-crystal structures with a native and an engineered activation motif, revealing insights into its autocleavage activation and distinct substrate binding cleft features. Leveraging this structural data, we develop nanomolar potency peptidomimetic inhibitors of TMPRSS11D and TMPRSS2. We show that a broad serine protease inhibitor that underwent clinical trials for TMPRSS2-targeted COVID-19 therapy, nafamostat mesylate, was rapidly cleaved by TMPRSS11D and converted to low activity derivatives. In this work, we develop mechanistic insights into human protease viral tropism and highlight both the strengths and limitations of existing human serine protease inhibitors, informing future drug discovery efforts targeting these proteases.